Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Catalyst Pharmaceuticals Inc CPRX

Healthcare Biotechnology
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for... see more

NDAQ:CPRX - Post Discussion

Catalyst Pharmaceuticals Inc > CATALYST PHARMACEUTICALS: NEXT BIG THING ON S&P SMALLCAP 600
View:
Post by AviseAnalytics on Sep 14, 2022 8:39am

CATALYST PHARMACEUTICALS: NEXT BIG THING ON S&P SMALLCAP 600

$CPRX

Excited to share an article about Catalyst Pharmaceuticals, Inc (NASDAQ: CPRX), a commercial-stage biopharmaceutical company that is expected to replace Mantech International Corp (NASDAQ: MANT) on the S&P SmallCap 600 from September 15, 2022.

It has several new developments in the pipeline which make it worth watching out for!

Read on to know more:

https://www.aviseanalytics.com/catalyst-pharmaceuticals-next-big-thing-on-sp-smallcap-600/

Be the first to comment on this post
Catalyst Pharmaceuticals Inc